PERTH, Australia – Epi-Minder Pty. Ltd. has completed an oversubscribed series A round of AU$18 million (US$12.89 million) that will see its Minder epilepsy monitoring device enter a pivotal trial to support marketing applications in Europe and the U.S. The smartphone-enabled device promises to improve on wearables and other tools – such as patient diaries – that have proven to be unreliable.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bruin Biometrics, Cytosorbents, Key Surgical, Steris, Wise Therapeutics.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Beckman Coulter, Genmark Diagnostics, Oxford Nanopore.
Keeping you up to date on recent developments in neurology, including: Hydrogel developed to help repair damaged nerves; Evidence of Alzheimer’s, Parkinson’s & MND in brains of young people exposed to dirty air; Study identifies brain cells most affected by epilepsy and new targets for their treatment.
Investigators at the University of Heidelberg have identified a previously unknown mechanism for excitotoxicity and used their insight to identify “unconventional neuroprotectant” compounds that could prevent cell death and reduce brain damage in a mouse model of stroke.
RSS
